MYGN

Myriad Genetics, Inc. - 10-Q Filing Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended March 31, 2006. Myriad Genetics, Inc. is a biotechnology company focused on predictive medicine products (genetic testing) and the development of therapeutic drugs for major diseases including Alzheimer's, cancer, and AIDS. The company operates three segments: Research, Predictive Medicine, and Drug Development.

Key Financial Metrics

Margins: Predictive medicine gross profit margin was 72% for the three months ended March 31, 2006, and 73% for the nine-month period.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 49% for the three months and 46% for the nine months compared to the prior year periods. Predictive medicine revenue grew 46% (quarterly) and 43% (year-to-date), driven by increased sales and marketing efforts.
• Expense Increases: Research and development (R&D) expenses rose 41% quarterly and 38% year-to-date, primarily due to expanded clinical trials (Flurizan, Azixa) and drug discovery programs. Selling, general, and administrative (SG&A) expenses increased 25% quarterly and 14% year-to-date to support business growth.
• Liquidity Improvement: Cash and marketable securities increased by approximately $115.5 million from June 30, 2005, to March 31, 2006. This was primarily due to net proceeds of $139.7 million from a public offering of common stock in November 2005.
• Net Loss Reduction: While the company remains unprofitable, the net loss for the nine months ended March 31, 2006 ($26.8 million) was lower than the prior year period ($30.0 million), aided by increased interest income ($4.9 million vs. $2.0 million) resulting from higher cash balances.

Guidance, Outlook, and Risks

Outlook: Management expects to incur losses for at least the next several years due to the expansion of drug discovery, clinical trials, and the launch of new predictive medicine products. The company believes its current capital resources are sufficient to fund operations for at least the next two years.

Key Developments:

• Flurizan (Alzheimer's): Phase 3 trial enrollment has begun for mild Alzheimer's disease. Phase 2 follow-on data showed 34-45% slowing in decline for patients on the 800 mg twice-daily dose.
• Flurizan (Prostate Cancer): Phase 2b trial is ongoing to assess the ability to delay metastasis.
• Azixa & MPC-2130: Phase 1 trials are underway for solid tumors/brain metastases and blood cancers, respectively.
• MPC-0920: Phase 1 trial for thrombosis initiated in April 2006.

Risks and Contingencies:

• Success depends heavily on the results of clinical trials for Flurizan and other drug candidates.
• Regulatory approval is required for therapeutic products; delays or rejections could materially impact the business.
• The company relies on predictive medicine revenues to fund operations; future growth is not guaranteed.
• Intellectual property protection and potential patent infringement claims.

Investor Verification Checklist

• Verify the enrollment progress and interim data from the Phase 3 Flurizan trial for Alzheimer's disease.
• Monitor the timeline and results of the Phase 2b Flurizan trial for prostate cancer.
• Review the sustainability of the 72-73% gross margin in the predictive medicine segment as new products are introduced.
• Assess the burn rate of cash relative to the $229.3 million in liquid assets to confirm the "two-year runway" estimate.
• Track the status of regulatory filings (INDs) for preclinical candidates MPI-49839 (AIDS) and MPC-4505 (Emesis).